DK1508047T3 - Fremgangsmåde til identifikation af immunoreaktive peptider - Google Patents

Fremgangsmåde til identifikation af immunoreaktive peptider

Info

Publication number
DK1508047T3
DK1508047T3 DK03735383T DK03735383T DK1508047T3 DK 1508047 T3 DK1508047 T3 DK 1508047T3 DK 03735383 T DK03735383 T DK 03735383T DK 03735383 T DK03735383 T DK 03735383T DK 1508047 T3 DK1508047 T3 DK 1508047T3
Authority
DK
Denmark
Prior art keywords
peptides
immunoreactive peptides
identifying
tumorous
identifying immunoreactive
Prior art date
Application number
DK03735383T
Other languages
English (en)
Inventor
Toni Weinschenk
Hans Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK1508047T3 publication Critical patent/DK1508047T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03735383T 2002-05-29 2003-05-14 Fremgangsmåde til identifikation af immunoreaktive peptider DK1508047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225139A DE10225139A1 (de) 2002-05-29 2002-05-29 Verfahren zur Identifizierung von immunreaktiven Peptiden
PCT/EP2003/005038 WO2003100432A2 (de) 2002-05-29 2003-05-14 Verfahren zur identifizierung von immunreaktiven peptiden

Publications (1)

Publication Number Publication Date
DK1508047T3 true DK1508047T3 (da) 2008-10-20

Family

ID=29557590

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03735383T DK1508047T3 (da) 2002-05-29 2003-05-14 Fremgangsmåde til identifikation af immunoreaktive peptider

Country Status (13)

Country Link
EP (1) EP1508047B1 (da)
JP (1) JP2005535299A (da)
AT (1) ATE403874T1 (da)
AU (1) AU2003236645B2 (da)
CA (1) CA2486738C (da)
CY (1) CY1108358T1 (da)
DE (2) DE10225139A1 (da)
DK (1) DK1508047T3 (da)
ES (1) ES2311710T3 (da)
IL (2) IL165398A0 (da)
PT (1) PT1508047E (da)
SI (1) SI1508047T1 (da)
WO (1) WO2003100432A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005023488D1 (de) * 2004-06-17 2010-10-21 Mannkind Corp Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
EP1994181A4 (en) * 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
AU2022318257A1 (en) 2021-07-27 2024-02-08 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding ct45

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide

Also Published As

Publication number Publication date
WO2003100432A3 (de) 2004-06-03
DE10225139A1 (de) 2004-02-26
DE50310283D1 (de) 2008-09-18
PT1508047E (pt) 2008-10-02
SI1508047T1 (sl) 2008-12-31
AU2003236645B2 (en) 2009-06-18
CY1108358T1 (el) 2014-02-12
CA2486738A1 (en) 2003-12-04
ATE403874T1 (de) 2008-08-15
JP2005535299A (ja) 2005-11-24
CA2486738C (en) 2011-07-12
EP1508047A2 (de) 2005-02-23
IL165398A (en) 2013-04-30
ES2311710T3 (es) 2009-02-16
WO2003100432A2 (de) 2003-12-04
IL165398A0 (en) 2006-01-15
AU2003236645A1 (en) 2003-12-12
EP1508047B1 (de) 2008-08-06

Similar Documents

Publication Publication Date Title
DK1508047T3 (da) Fremgangsmåde til identifikation af immunoreaktive peptider
ATE478381T1 (de) Verfahren zur bearbeitung von daten
EA199900162A1 (ru) Ингибиторы клеточной адгезии
ATE439380T1 (de) Methoden zur herstellung humaner monoklonaler antikörper
CY1110295T1 (el) Trans-9,10-δεϋδροεποθιλονη c και d, αναλογα αυτων και μεθοδοι παρασκευης
WO2005058018A3 (en) System and method for plant identification
NO20063304L (no) Fremgangsmate til a rense FSH
EA200001129A2 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ATE427127T1 (de) Bioaktive beschichtung fur medizinische vorrichtung mit keratin
DE60139466D1 (de) Behandlung von diabetes
EP1090294A4 (en) METHOD FOR DETERMINING THE PRESENCE OF CANCER IN A SAMPLE BY DETECTING THE EXPRESSION OF A SSX GENE AND PEPTIDES DERIVED FROM SSX OR NY-ESO-1
ES2061863T3 (es) Nuevas quinoliloxazol-2-onas utiles como inhibidores de proteina quinasa c.
WO2005027859A3 (en) Patch
ATE530982T1 (de) Usb-gerät
DK1290160T3 (da) Humane Pellino-polypeptider
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
NO20062657L (no) Cytokinantagonistmolekyler
ATE427967T1 (de) Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)
SE0200383D0 (sv) A method and a system for a data processor
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
EP1187336A3 (en) Compression in the presence of shared data
ATE445842T1 (de) Nachweis spezifischer nitrierter marker
ATE374990T1 (de) Verfahren zum synthetisieren von sprache
ATE500273T1 (de) Methoden zur analyse von antikörperdisulfidisomere